Abstract
The Vesicular Acetylcholine Transporter (VAChT) is found throughout the cholinergic nervous system and is responsible for transporting Acetylcholine (ACh) into synaptic vesicles for storage. Deterioration of cholinergic neurotransmission is a known pathophysiological hallmark of Alzheimers disease (AD). Ligands that bind to VAChT – particularly in the brain and CNS where cholinergic neurotransmission is vital for memory and cognitive function – may facilitate the study of cholinergic pathway regulation in the CNS and serve as useful diagnostic agents for AD. Vesamicol was the first VAChT ligand identified, however its poor selectivity has prompted the search for more potent and selective compounds. Numerous structural modifications to the vesamicol scaffold have been explored and several classes of VAChT ligands are highlighted in this review. The affinity and selectivity of these ligands for VAChT and -receptors are discussed.
Keywords: Alzheimer's disease, benzovesamicol, CNS, structure-activity relationship, VAChT, vesamicol
Current Bioactive Compounds
Title: Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease
Volume: 6 Issue: 3
Author(s): Nicolas Giboureau, Kylee M. Aumann, Corinne Beinat and Michael Kassiou
Affiliation:
Keywords: Alzheimer's disease, benzovesamicol, CNS, structure-activity relationship, VAChT, vesamicol
Abstract: The Vesicular Acetylcholine Transporter (VAChT) is found throughout the cholinergic nervous system and is responsible for transporting Acetylcholine (ACh) into synaptic vesicles for storage. Deterioration of cholinergic neurotransmission is a known pathophysiological hallmark of Alzheimers disease (AD). Ligands that bind to VAChT – particularly in the brain and CNS where cholinergic neurotransmission is vital for memory and cognitive function – may facilitate the study of cholinergic pathway regulation in the CNS and serve as useful diagnostic agents for AD. Vesamicol was the first VAChT ligand identified, however its poor selectivity has prompted the search for more potent and selective compounds. Numerous structural modifications to the vesamicol scaffold have been explored and several classes of VAChT ligands are highlighted in this review. The affinity and selectivity of these ligands for VAChT and -receptors are discussed.
Export Options
About this article
Cite this article as:
Giboureau Nicolas, M. Aumann Kylee, Beinat Corinne and Kassiou Michael, Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease, Current Bioactive Compounds 2010; 6 (3) . https://dx.doi.org/10.2174/157340710793237353
DOI https://dx.doi.org/10.2174/157340710793237353 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
T-type Calcium Channels in Health and Disease
Current Medicinal Chemistry Computer-Assisted Methods in Chemical Toxicity Prediction
Mini-Reviews in Medicinal Chemistry Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews New Recombinant Serotypes of AAV Vectors
Current Gene Therapy PDE-5 Inhibitors for BPH-Associated LUTS
Current Drug Targets Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry Hypertensive Heart Disease and the Role of Aldosterone Antagonists
Current Hypertension Reviews Assessing Medication Problems in those ≥ 65 Using the STOPP and START Criteria
Current Aging Science Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism Hypertension and Heart Failure with Preserved Ejection Fraction: Connecting the Dots
Current Vascular Pharmacology Renin Angiotensin System (RAS) and Immune System Profile in Specific Subgroups with COVID-19
Current Medicinal Chemistry Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
Current Clinical Pharmacology The Effects of Aerobic Exercise on Cognitive Function of Alzheimer's Disease Patients
CNS & Neurological Disorders - Drug Targets Therapeutically Targeting MicroRNAs in Liver Cancer
Current Pharmaceutical Design Integral Therapeutic Potential of Bone Marrow Mesenchymal Stem Cells
Current Drug Targets Vascular effects of flavonoids
Current Medicinal Chemistry Turner Syndrome : How Is It Made Up?
Current Genomics Systematic Review of Glucagon-Like Peptide One Receptor Agonist Liraglutide of Subjects with Heart Failure with Reduced Left Ventricular Ejection Fraction
Current Diabetes Reviews The Pathophysiology of Sleep Apnoea: What We have Learned from Animal Models of Chronic Intermittent Hypoxia
Current Respiratory Medicine Reviews